Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Sep
Source: Bse
Industrials stocks · Micro cap · NSE
GMM Pfaudler Limited manufactures process equipment, providing glass-lined and non-glass-lined technologies, systems, and services globally. It serves diverse sectors including pharmaceuticals, chemicals, oil & gas, and defense.
SMA20 +19.8% / mo · MACD −
Latest mapped FPI equity flow was not positive. View sector evidence
Adjusted completed-session prices, rebased to 100
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +16.4% · PAT +120.0% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +16% YoY · PAT +120% YoY · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹925 Cr | +16.4% | -2.0% |
| EBITDA | ₹94 Cr | -6.9% | +25.3% |
| Operating margin | 10.0% | -300 bps | +200 bps |
| PAT | ₹22 Cr | +120.0% | +46.7% |
| PAT margin | 2.4% | +112 bps | +79 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 19/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Signals are conflicting — long-term uptrend intact. RSI 45. Wait for confirmation.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 21 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
For this sector, IndiaPulse uses a blended lens rather than relying on a single valuation ratio.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
FY26 Consolidated Revenue up 10% YoY to ₹3,524 Cr, EBITDA up 11% to ₹403 Cr (11.4% margin). Order Intake surged 20% YoY to ₹3,714 Cr, with Backlog up 34% YoY to ₹2,194 Cr. Q4 FY26 Revenue grew 17% YoY, but EBITDA declined 10% YoY.
Strong order intake and backlog growth for FY26 indicate robust demand and future revenue visibility. However, Q4 FY26 saw a notable decline in consolidated EBITDA margin and absolute EBITDA, raising questions about execution efficiency and cost management in the short term. Adjusted PAT shows better underlying profitability.
Latest issuer-disclosed distribution across 3 reported categories.
Consolidated Order Intake grew 20% YoY in FY26 to ₹3,714 Cr, indicating robust demand across segments.
Backlog increased 34% YoY to ₹2,194 Cr, providing significant revenue visibility for future periods.
Diversification strategy gaining momentum, with Pharmaceuticals and Chemicals contributing significantly to order intake.
Net Debt/Equity improved to 0.1x and Net Debt/Adj. EBITDA to 0.4x, indicating stronger financial health.
Free cash flow generation for FY26 was ₹367 crores, up from ₹318 crores in FY25.
Consolidated EBITDA declined 10% YoY in Q4 FY26, with margin contracting by 236 bps YoY and 392 bps QoQ.
FY26 PAT includes exceptional items of ₹47 Cr (net of tax) related to Labour Code provision and Waghäusel severance costs.
Receivable days increased to 48 and Payable days to 49, indicating potential pressure on working capital management.
The significant QoQ and YoY decline in Q4 consolidated EBITDA margin suggests potential execution or cost control challenges that need monitoring.
Increase in receivable and payable days could indicate a less efficient working capital cycle, potentially impacting cash flow.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
FY26 results provide annual performance and strategic direction, while Q4 FY26 data offers recent operational momentum and margin trends, crucial for assessing sequential execution and any immediate challenges.
Consolidated Order Intake for FY26 was ₹3,714 Cr, up 20% YoY. Q4 FY26 Order Intake was ₹871 Cr, up 32% YoY.
Consolidated Backlog as of March 31, 2026, was ₹2,194 Cr, up 34% YoY.
Consolidated Revenue for FY26 was ₹3,524 Cr, up 10% YoY. Q4 FY26 Revenue was ₹944 Cr, up 17% YoY.
Consolidated EBITDA margin for FY26 was 11.4% (up from 11.3% in FY25). Q4 FY26 EBITDA margin was 8.0% (down from 10.3% in Q4 FY25 and 11.9% in Q3 FY26).
Mr. Gregory Gelhaus appointed as Group Chief Executive Officer and Mr. Ankit Nayyar as Deputy Chief Financial Officer.
The Board recommended a final dividend of ₹1 per equity share, bringing the total dividend for FY26 to ₹2 per share.
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Consolidated EBITDA Margin | 8.0% (Q4 FY26) | Stabilization and improvement from Q4 levels, especially given the strong order book. |
| Order Intake Growth | 20% YoY (FY26) | Continued double-digit growth to sustain backlog and revenue pipeline. |
| Working Capital Cycle | Receivable days 48, Payable days 49 | Improvement in receivable and payable days to optimize cash conversion. |
| Exceptional Items | ₹47 Cr (FY26 net) | Resolution of exceptional items and their impact on adjusted profitability in future periods. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 50th percentile within Industrials. Main check: financial discipline is weak at 52/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · Industrials: 50th pctile, median 68 · Micro: 32nd pctile, median 73
116 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse